Synektik (FRA:A2P) ROCE % : 25.89% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Synektik ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synektik's annualized ROCE % for the quarter that ended in Mar. 2024 was 25.89%.

Synektik ROCE % Historical Data

The historical data trend for Synektik's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synektik ROCE % Chart

Synektik Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Sep18

Sep19

Sep20

Sep21

Sep22

ROCE %

Get a 7-Day Free Trial

15.54

14.72

11.95

10.21

11.64

Synektik Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															12.42	51.80	36.40	95.52	25.89

Synektik ROCE % Calculation

Synektik's annualized ROCE % for the fiscal year that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	3.157	/	( ( (36.679 - 12.641)	+	(54.318 - 24.097) )	/ 2 )
	=	3.157	/	( (24.038	+	30.221)	/ 2 )
	=	3.157	/	27.1295
	=	11.64 %

Synektik's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	12.02	/	( ( (91.319 - 43.594)	+	(74.087 - 28.956) )	/ 2 )
	=	12.02	/	( ( 47.725	+	45.131 )	/ 2 )
	=	12.02	/	46.428
	=	25.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Synektik (FRA:A2P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synektik ROCE % Related Terms

Thank you for viewing the detailed overview of Synektik's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synektik (FRA:A2P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Synektik SA (FRA:A2P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SNT:Poland

Address

Aleja Wincentego Witosa 31, Warsaw, POL, 00-710

Website

http://www.synektik.pl

Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.

Synektik (FRA:A2P) Headlines

No Headlines